Гонорея: cовременное состояние вопроса с диагностикой и лечением

1. Bignell C. Int J STD AIDS 2009; 20 (7): 453–7.
2. Kent CK et al. Clin Infect Dis 2005; 41: 67–74.
3. Stefanski P, Hafner JW, Riley SL et al. Diagnostic utility of the genital Gram stain in ED patients. Am J Emerg Med 2010; 28: 13–8.
4. Geisler WM, Yu S, Hook EW. 3rd. Chlamydial and gonococcal infection in men without polymorphonuclear leukocytes on gram stain: implications for diagnostic approach and management. Sexually transmitted diseases 2005; 32: 630–4.
5. Приказ МЗиСР РФ №176 от 25.02.2005 «Об утверждении стандарта медицинской помощи больным гонококковой инфекцией».
6. CDC. Sexually transmitted diseases treatment guidelines, 2006. Morbidity and Mortality Weekly Report (MMWR) 2006; 55: 1–94.
7. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44 (Suppl. 3): S84–101.
8. WHO. Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization, 2003.
9. Резистентность возбудителей ИППП к антибактериальным препаратам. Информационный бюллетень 2009. М.: ДЭКС-ПРЕСС, 2009.
10. Kubanova A, Frigo N, Kubanov A et al. The Russian gonococcal antimicrobial susceptibility programme (RU-GASP) – national resistance prevalence in 2007 and 2008, and trends during 2005–2008. Euro Surveill 2010; 15 (14): 1–5.
11. Centers for Disease Control and Prevention. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections MMWR Morb Mortal Wkly Rep 2007; 56 (14): 332–6.
12. Ison CA, Mouton JW, Jones K et al. Which cephalosporin for gonorrhoea? Sex Transm Infect 2004; 80: 386–8.
13. Vorobieva V, Firsova N et al. Antibiotic susceptibility of Neisseria gonorrhoeae in Arkhangelsk, Russia. Sex Transm Infect 2007; 83 (2): 133–5.
14. Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009; 85 (4): 256–8.
15. Tapsall J, Read P et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009; 58 (Pt 5): 683–7.
16. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 2009; 22: 87–91.
17. Lo JY, Ho KM et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008; 52 (10): 3564–7.
18. Hook EW et al. Antimicrob Аgents Chemother 1997; 8: 1843–5.
19. Wang SA, Harvey AB, Conner SM et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 2007; 147 (2): 81–8.
20. Unemo M, Shipitsyna E, Domeika M. On behalf of the Eastern European Sexual and Reproductive Health (EE SRH) Network Antimicrobial Resistance Group. Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial. Sex Transm Infect 2010 May 10.